Drug Profile
Research programme: peptide conjugates - Amunix/PolyPeptide Laboratories
Latest Information Update: 09 Feb 2022
Price :
$50
*
At a glance
- Originator Amunix; Polypeptide Laboratories
- Class Peptides; Recombinant fusion proteins
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 17 Jan 2022 Amunix has been acquired by Sanofi
- 28 Nov 2018 No recent reports of development identified for research development in Unspecified in USA
- 28 Oct 2014 Early research in Undefined indication in USA (unspecified route)